Product NDC: | 63323-120 |
Proprietary Name: | Cytarabine |
Non Proprietary Name: | CYTARABINE |
Active Ingredient(s): | 100 mg/mL & nbsp; CYTARABINE |
Administration Route(s): | INTRATHECAL; INTRAVENOUS; SUBCUTANEOUS |
Dosage Form(s): | INJECTION, SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 63323-120 |
Labeler Name: | APP Pharmaceuticals, LLC |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA076512 |
Marketing Category: | ANDA |
Start Marketing Date: | 20041129 |
Package NDC: | 63323-120-20 |
Package Description: | 1 VIAL, SINGLE-DOSE in 1 CARTON (63323-120-20) > 20 mL in 1 VIAL, SINGLE-DOSE |
NDC Code | 63323-120-20 |
Proprietary Name | Cytarabine |
Package Description | 1 VIAL, SINGLE-DOSE in 1 CARTON (63323-120-20) > 20 mL in 1 VIAL, SINGLE-DOSE |
Product NDC | 63323-120 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | CYTARABINE |
Dosage Form Name | INJECTION, SOLUTION |
Route Name | INTRATHECAL; INTRAVENOUS; SUBCUTANEOUS |
Start Marketing Date | 20041129 |
Marketing Category Name | ANDA |
Labeler Name | APP Pharmaceuticals, LLC |
Substance Name | CYTARABINE |
Strength Number | 100 |
Strength Unit | mg/mL |
Pharmaceutical Classes | Nucleic Acid Synthesis Inhibitors [MoA],Nucleoside Metabolic Inhibitor [EPC] |